|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
|
16258541 |
2005 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer.
|
17510392 |
2007 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.
|
17671147 |
2007 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The T790M mutation is present in about half of the lung cancer patients with acquired resistance, and reported to act by increasing the affinity of the receptor to adenosine triphosphate, relative to its affinity to TKIs.
|
19096299 |
2009 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET.
|
19351834 |
2009 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de novo and acquired resistance to irreversible EGFR-TKIs in lung cancer harboring T790M mutation in EGFR.
|
20008840 |
2010 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
|
21062933 |
2010 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
|
21135146 |
2011 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that EMT developed in a lung cancer patient who had an acquired resistance to erlotinib while there were no known resistant mechanisms such as T790M and MET amplification.
|
21168239 |
2011 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
|
21248300 |
2011 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of low-level EGFR T790M mutation in lung cancer tissues.
|
21635547 |
2011 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amplification in tumors with intrinsic and acquired EGFR-TKI resistance in EGFR mutant lung cancer in Japanese patients.
|
22052230 |
2011 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The effects of E7050 on HGF-induced resistance to reversible (gefitinib), irreversible (BIBW2992), and mutant-selective (WZ4002) EGFR-TKIs were determined using the EGFR mutant human lung cancer cell lines PC-9 and HCC827 with an exon 19 deletion and H1975 with an T790M secondary mutation.
|
22317763 |
2012 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The three major clinically relevant mechanisms of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant lung cancer are a second mutation in the EGFR gene (T790M), Met amplification, and increased expression of hepatocyte growth factor (HGF).
|
22592212 |
2012 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation.
|
22751098 |
2012 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
|
22899358 |
2012 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation.
|
23045273 |
2013 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
|
23185274 |
2012 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, knock-down of T790M transcript by siRNAs further decreases the cell growth of T790M mutant lung cancer cells that are treated with TKIs or cetuximab.
|
23266614 |
2013 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.
|
23588221 |
2013 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients with lung cancer has been linked to acquisition of the T790M resistance mutation in activated EGFR or amplification of MET.
|
23592446 |
2013 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant.
|
23664448 |
2013 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In EGFR mutant lung cancer, modeling of acquired resistance (AR) with drug-sensitive cell lines has identified clinically relevant EGFR tyrosine kinase inhibitor (TKI) resistance mechanisms such as the second-site mutation, EGFR T790M, amplification of the gene encoding an alternative kinase, MET, and epithelial-mesenchymal transition (EMT).
|
23733853 |
2013 |